Yonsei Med J.  2017 Mar;58(2):319-325. 10.3349/ymj.2017.58.2.319.

Serum Chemerin Levels are Associated with Visceral Adiposity, Independent of Waist Circumference, in Newly Diagnosed Type 2 Diabetic Subjects

• Cheon DY
• Kang JG
• Lee SJ
• Ihm SH
• Lee EJ
• Choi MG
• Yoo HJ
• Kim CS

• KMID: 2427120
• DOI: http://doi.org/10.3349/ymj.2017.58.2.319

Abstract

PURPOSE
Chemerin has been suggested to be linked to insulin resistance and type 2 diabetes mellitus (T2DM). However, the relationship between visceral adiposity and chemerin levels remains unclear in subjects with T2DM. In this study, we investigated the relationship between serum chemerin levels and visceral adiposity.
MATERIALS AND METHODS
This study included 102 subjects newly diagnosed with T2DM. The relationships between serum chemerin levels and clinical and biochemical parameters were examined. Multiple linear regression analysis was performed to determine the predictable factors of serum chemerin levels.
RESULTS
Serum chemerin levels showed significant positive correlations with body mass index (BMI), waist circumference (WC), visceral fat thickness (VFT), insulin levels, the homeostasis model assessment of insulin resistance, and levels of triglycerides (log-transformed) and high-sensitivity C-reactive protein, while showing significant negative correlations with high-density lipoprotein cholesterol. After adjusting for BMI and WC, VFT showed a significant relationship with serum chemerin levels (r=0.222, p=0.027). Moreover, VFT was an independent predictive factor of serum chemerin levels (β=0.242, p=0.041).
CONCLUSION
We demonstrated that chemerin is linked to metabolic syndrome components. Moreover, serum chemerin levels were associated significantly with obesity, especially visceral adipose tissue, in subjects with T2DM.

Keyword

Chemerin; visceral fat; type 2 diabetes mellitus

MeSH Terms

Adiposity
Adult
Biomarkers/blood
Body Mass Index
C-Reactive Protein/metabolism
Chemokines/blood/metabolism
Cholesterol, HDL/blood
Diabetes Mellitus, Type 2/blood/complications/diagnosis
Female
Humans
Insulin Resistance
Intercellular Signaling Peptides and Proteins
*Intra-Abdominal Fat
Male
Metabolic Syndrome/complications
Middle Aged
Obesity/complications
Triglycerides/blood
*Waist Circumference
Biomarkers
Chemokines
Cholesterol, HDL
Intercellular Signaling Peptides and Proteins
Triglycerides
C-Reactive Protein

Figure

• 

  Fig. 1 (A) Relationship between serum chemerin levels and body mass index. (B) Relationship between serum chemerin levels and waist circumference. (C) Relationship between serum chemerin levels and visceral fat thickness.

Reference

1. Kim CS, Ko SH, Kwon HS, Kim NH, Kim JH, Lim S, et al. Prevalence, awareness, and management of obesity in Korea: data from the Korea national health and nutrition examination survey (1998-2011). Diabetes Metab J. 2014; 38:35–43.

2. Zheng W, McLerran DF, Rolland B, Zhang X, Inoue M, Matsuo K, et al. Association between body-mass index and risk of death in more than 1 million Asians. N Engl J Med. 2011; 364:719–729.

3. Larsson B, Svärdsudd K, Welin L, Wilhelmsen L, Björntorp P, Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed). 1984; 288:1401–1404.

4. Jung SH, Ha KH, Kim DJ. Visceral fat mass has stronger associations with diabetes and prediabetes than other anthropometric obesity indicators among Korean adults. Yonsei Med J. 2016; 57:674–680.

5. Ducimetiere P, Richard J, Cambien F. The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris Prospective study. Int J Obes. 1986; 10:229–240.

6. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007; 148:4687–4694.

7. Goralski KB, McCarthy TC, Hanniman EA, Zabel BA, Butcher EC, Parlee SD, et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem. 2007; 282:28175–28188.

8. Yang M, Yang G, Dong J, Liu Y, Zong H, Liu H, et al. Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension. J Investig Med. 2010; 58:883–886.

9. Bozaoglu K, Segal D, Shields KA, Cummings N, Curran JE, Comuzzie AG, et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab. 2009; 94:3085–3088.

10. Shin HY, Lee DC, Chu SH, Jeon JY, Lee MK, Im JA, et al. Chemerin levels are positively correlated with abdominal visceral fat accumulation. Clin Endocrinol (Oxf). 2012; 77:47–50.

11. Han J, Kim SH, Suh YJ, Lim HA, Shin H, Cho SG, et al. Serum chemerin levels are associated with abdominal visceral fat in type 2 diabetes. J Korean Med Sci. 2016; 31:924–931.

12. Oh SW, Shin SA, Yun YH, Yoo T, Huh BY. Cut-off point of BMI and obesity-related comorbidities and mortality in middle-aged Koreans. Obes Res. 2004; 12:2031–2040.

13. Lee SY, Park HS, Kim DJ, Han JH, Kim SM, Cho GJ, et al. Appropriate waist circumference cutoff points for central obesity in Korean adults. Diabetes Res Clin Pract. 2007; 75:72–80.

14. Weigert J, Neumeier M, Wanninger J, Filarsky M, Bauer S, Wiest R, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf). 2010; 72:342–348.

15. Ridker PM. High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease. Circulation. 2001; 103:1813–1818.

16. Muruganandan S, Parlee SD, Rourke JL, Ernst MC, Goralski KB, Sinal CJ. Chemerin, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) target gene that promotes mesenchymal stem cell adipogenesis. J Biol Chem. 2011; 286:23982–23995.

17. Esteghamati A, Ghasemiesfe M, Mousavizadeh M, Noshad S, Nakhjavani M. Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes. J Diabetes Investig. 2014; 5:327–332.

18. Hu W, Feng P. Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients. Diabetes Res Clin Pract. 2011; 91:159–163.

19. Wittamer V, Franssen JD, Vulcano M, Mirjolet JF, Le Poul E, Migeotte I, et al. Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids. J Exp Med. 2003; 198:977–985.

20. Lehrke M, Becker A, Greif M, Stark R, Laubender RP, von Ziegler F, et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol. 2009; 161:339–344.

21. Ernst MC, Sinal CJ. Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab. 2010; 21:660–667.

22. Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population--a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2008; 152:217–221.

23. Jialal I, Devaraj S, Kaur H, Adams-Huet B, Bremer AA. Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome. J Clin Endocrinol Metab. 2013; 98:E514–E517.

24. Gu P, Jiang W, Lu B, Shi Z. Chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients. Clin Exp Hypertens. 2014; 36:326–332.

25. Hah YJ, Kim NK, Kim MK, Kim HS, Hur SH, Yoon HJ, et al. Relationship between chemerin levels and cardiometabolic parameters and degree of coronary stenosis in Korean patients with coronary artery disease. Diabetes Metab J. 2011; 35:248–254.

26. Lin X, Tang X, Jiang Q, Liu Q, Lin Z, Lin J, et al. Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes. Clin Lab. 2012; 58:539–544.

27. Chaowalit N, Somers VK, Pellikka PA, Rihal CS, Lopez-Jimenez F. Subepicardial adipose tissue and the presence and severity of coronary arterydisease. Atherosclerosis. 2006; 186:354–359.

28. Stevens-Simon C, Thureen P, Stamm E, Scherzinger A. A comparison of four techniques for measuring central adiposity in postpartum adolescents. J Matern Fetal Med. 2001; 10:209–213.

29. Shen W, Punyanitya M, Wang Z, Gallagher D, St-Onge MP, Albu J, et al. Visceral adipose tissue: relations between single-slice areas and total volume. Am J Clin Nutr. 2004; 80:271–278.

30. Stolk RP, Meijer R, Mali WP, Grobbee DE, van der Graaf Y. Secondary Manifestations of Arterial Disease Study Group. Ultrasound measurements of intraabdominal fat estimate the metabolic syndrome better than do measurements of waist circumference. Am J Clin Nutr. 2003; 77:857–860.

31. Kim SK, Kim HJ, Hur KY, Choi SH, Ahn CW, Lim SK, et al. Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases. Am J Clin Nutr. 2004; 79:593–599.

32. Hirooka M, Kumagi T, Kurose K, Nakanishi S, Michitaka K, Matsuura B, et al. A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography. Intern Med. 2005; 44:794–799.